Benralizumab strongly reduces blood basophils in severe eosinophilic asthma

Clin Exp Allergy. 2020 Nov;50(11):1267-1269. doi: 10.1111/cea.13720. Epub 2020 Aug 26.

Authors

Marek Lommatzsch¹, Hannes Marchewski¹, Georg Schwefel¹, Paul Stoll¹, Johann Christian Virchow¹, Kai Bratke¹

Affiliation

¹ Department of Pneumology and Critical Care Medicine, University of Rostock, Rostock, Germany.

PMID: 32762056
DOI: 10.1111/cea.13720

No abstract available

Publication types

Clinical Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / blood
Asthma / diagnosis
Asthma / drug therapy*
Asthma / immunology
Basophils / drug effects*
Basophils / immunology
Case-Control Studies
Eosinophilia / blood
Eosinophilia / diagnosis
Eosinophilia / drug therapy*
Eosinophilia / immunology
Female
Humans
Leukocyte Count
Male
Middle Aged
Severity of Illness Index
Time Factors
Treatment Outcome

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
benralizumab

Associated data

ClinicalTrials.gov/NCT03652376